Take Homes for Your Practice from Princeton 4: ED, CVD, and Sexual Function

madman · 2025-05-08T22:24:11-0500

* PDE5 meds MAY reduce MI, Stroke & Mortality

Take Homes for Your Practice from Princeton 4: ED, CVD, and Sexual Function - Martin Miner, MD and Noel N. Kim, PhD

Members of the Princeton 4 Commitee

madman · 2025-05-08T22:26:37-0500

Concluding Remarks

madman · 2025-05-08T22:29:13-0500

Conclusions: PDE5 Inhibitors in Women

madman · 2025-05-08T22:33:32-0500

Thread 'PDE5 inhibitors (Cialis, Viagra, etc) and cardiac health: Princeton IV consensus guidelines:'

Dec 27, 2023

Been waiting on this one.

Damn, that is deep!

Abstract

Background

In 1999, 1 year after the approval of the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction(ED), the first Princeton Consensus Conference was held to address the clinical management of men with ED who also had cardiovascular disease. These issues were readdressed in the second and third conferences. In the 13 years since the last Princeton Consensus Conference, the experience with PDE5 inhibitors is more robust, and recent new data have emerged regarding not only...

madman · 2025-05-08T22:34:36-0500

Thread 'Recommendations for the Management of ED and Cardiovascular Disease'

Aug 11, 2024

The main lessons from the article are:

Independent Risk Marker: Erectile dysfunction (ED) should be considered an independent risk marker for coronary artery disease (CAD). It predates significant cardiac events, including myocardial infarctions and sudden cardiac deaths, often by several years. Thus, it can serve as an early indicator for potential cardiovascular issues.
Inclusion in Risk Calculators: The P4 panel advocates for the inclusion of ED as a risk-enhancing factor in cardiovascular risk assessment tools. Currently, only the QRISK calculator incorporates...